Literature DB >> 15348685

Limited compliance of some apatitic calcium phosphate bone cements with clinical requirements.

I Khairoun1, M G Boltong, F C Driessens, J A Planell.   

Abstract

Clinical requirements for calcium phosphate bone cements were formulated in terms of the initial setting time, the final setting time, the cohesion time and the ultimate compressive strength. Two cements were tested. Biocement H was made of a powder containing alpha-tertiary calcium phosphate and precipitated hydroxyapatite. Biocement F was made of a powder containing, in addition, some monetite. The liquid/powder (L/P) ratio was varied over the range 0.30-0.40 ml g(-1), whereas the accelerator concentration in the liquid was varied from 0%-4% Na2HPO4 in water. For Biocement H there was no combination L/P ratio and % Na2HPO4 for which all clinical requirements were satisfied. However, Biocement F had a certain area where this was the case. Therefore, it is expected that Biocement F can be applied in clinical situations such as orthopaedics, plastic and reconstructive surgery and oral and maxillofacial surgery, even when early contact with blood is inevitable. Copyright 1998 Kluwer Academic Publishers

Entities:  

Year:  1998        PMID: 15348685     DOI: 10.1023/a:1008939710282

Source DB:  PubMed          Journal:  J Mater Sci Mater Med        ISSN: 0957-4530            Impact factor:   3.896


  6 in total

1.  Compliance of an apatitic calcium phosphate cement with the short-term clinical requirements in bone surgery, orthopaedics and dentistry.

Authors:  M P Ginebra; E Fernández; M G Boltong; O Bermúdez; J A Planell; F C Driessens
Journal:  Clin Mater       Date:  1994

Review 2.  Evolution of bone transplantation: molecular, cellular and tissue strategies to engineer human bone.

Authors:  M J Yaszemski; R G Payne; W C Hayes; R Langer; A G Mikos
Journal:  Biomaterials       Date:  1996-01       Impact factor: 12.479

3.  Kinetic study of the setting reaction of a calcium phosphate bone cement.

Authors:  E Fernández; M P Ginebra; M G Boltong; F C Driessens; J Ginebra; E A De Maeyer; R M Verbeeck; J A Planell
Journal:  J Biomed Mater Res       Date:  1996-11

4.  Non-decay type fast-setting calcium phosphate cement: composite with sodium alginate.

Authors:  K Ishikawa; Y Miyamoto; M Kon; M Nagayama; K Asaoka
Journal:  Biomaterials       Date:  1995-05       Impact factor: 12.479

5.  Non-decay type fast-setting calcium phosphate cement: setting behaviour in calf serum and its tissue response.

Authors:  Y Miyamoto; K Ishikawa; M Takechi; M Yuasa; M Kon; M Nagayama; K Asaoka
Journal:  Biomaterials       Date:  1996-07       Impact factor: 12.479

6.  In vivo setting behaviour of fast-setting calcium phosphate cement.

Authors:  Y Miyamoto; K Ishikawa; H Fukao; M Sawada; M Nagayama; M Kon; K Asaoka
Journal:  Biomaterials       Date:  1995-07       Impact factor: 12.479

  6 in total
  5 in total

1.  Self-setting calcium orthophosphate formulations.

Authors:  Sergey V Dorozhkin
Journal:  J Funct Biomater       Date:  2013-11-12

2.  Development of a novel calcium phosphate cement composed mainly of calcium sodium phosphate with high osteoconductivity.

Authors:  Masashi Tanaka; Mitsuru Takemoto; Shunsuke Fujibayashi; Toshiyuki Kawai; Masako Tsukanaka; Kimiaki Takami; Satoshi Motojima; Hikaru Inoue; Takashi Nakamura; Shuichi Matsuda
Journal:  J Mater Sci Mater Med       Date:  2014-03-27       Impact factor: 3.896

3.  Ultrasound monitoring of the setting of calcium-based bone cements.

Authors:  M D Vlad; L González; S Gómez; J López; J E Carlson; E Fernández
Journal:  J Mater Sci Mater Med       Date:  2012-04-08       Impact factor: 3.896

4.  Direct and interactive influence of explanatory variables on properties of a calcium phosphate cement for vertebral body augmentation.

Authors:  Daniel M Werdofa; Gladius Lewis
Journal:  J Mater Sci Mater Med       Date:  2013-09-18       Impact factor: 3.896

5.  Bioresorbable porous β-tricalcium phosphate chelate-setting cements with poly(lactic-co-glycolic acid) particles as pore-forming agent: fabrication, material properties, cytotoxicity, and in vivo evaluation.

Authors:  Akihiro Ando; Maho Kamikura; Yuko Takeoka; Masahiro Rikukawa; Kazuaki Nakano; Masaki Nagaya; Hiroshi Nagashima; Mamoru Aizawa
Journal:  Sci Technol Adv Mater       Date:  2021-06-24       Impact factor: 8.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.